Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Veru Inc. (NASDAQ: VERU) Lands On The Street Ideas Watchlist This Morning—Tuesday, September 8, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Closer Look At (VERU) While It’s Still Early… September 8, 2026 Dear Reader, Ahead of this morning’s opening bell, Street Ideas is taking a closer look at a GLP-1 name tied to an issue the broader market rarely discusses. The GLP-1 revolution is real… Semaglutide and tirzepatide have reshaped how the world approaches obesity, and the numbers confirm it. According to Grand View Research, the global GLP-1 receptor agonist market was valued at $66.4B in 2025 and is projected to reach $185.3B by 2033, growing at a CAGR of 12.4%. 
That's not speculation. That's a sector generating real demand at enormous scale — and one that's still accelerating. The GLP-1 we-ight loss dr-ug market alone, according to Grand View Research, is projected to surge from $27.5B in 2026 to $48.8B by 2030 at a CAGR of 18.5%. But here's the part of the GLP-1 story that doesn't get nearly enough attention… When patients drop 15% to 25% of their body we-ight on GLP-1 RA therapy, a meaningful share of that reduction comes not from fat — but from lean muscle mass. For older adults already contending with diminished muscle reserves, that tradeoff could quietly undermine the very health gains the we-ight loss was supposed to deliver. Physical function declines. Fall risk goes up. Bone mineral density erodes. And the metabolic engine that burns energy at rest — muscle tissue itself — shrinks right alongside the fat. That's a real problem… and it's the exact problem a late-stage biopharmaceutical company out of Miami has built its entire pipeline to solve. Veru Inc. (NASDAQ: VERU) is developing enobosarm, an oral selective androgen receptor modulator (SARM) designed to work alongside GLP-1 RA dr-ugs — not to replace them, but to make we-ight reduction more tissue selective by maximizing fat loss while preserving the lean mass, physical function, and bone density that patients need to keep. Veru Inc. (NASDAQ: VERU) is topping our watchlist this morning—September 8, 2026. 
But keep in mind, (NASDAQ: VERU) has a float less than 16M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. And it’s important to mention, Canaccord Genuity analyst Edward Nash has a $25 target on VERU, which suggests significant upside potential from its recent $2.65 range. From Good We-ight Loss to Quality We-ight Loss
The conversation around GLP-1 RA therapies has mostly centered on total body we-ight reduction. But the clinical reality is more nuanced than a number on a scale… Rapid we-ight loss in older patients with obesity — particularly those over 65 — often comes with a cost that gets measured in lost muscle, diminished physical function, and weakened bone. Enobosarm was built to address exactly that gap. As a selective androgen receptor modulator, it selectively stimulates anabolic activity in muscle and bone tissue without the broader androgenic side effects associated with traditional androgen therapies. Think of it this way: GLP-1 RA therapies are a powerful engine for reducing total body we-ight — but they don't discriminate well between fat and muscle. Enobosarm is designed to add that layer of precision. The concept isn't to compete with semaglutide or tirzepatide… It's to complement them — to convert ordinary we-ight loss into what Veru Inc. (NASDAQ: VERU) calls "quality we-ight loss." And the early clinical data suggests the concept has legs. The company's completed Phase 2b QUALITY study — a randomized, double-blind, placebo-controlled trial in 168 older patients — demonstrated that enobosarm plus semaglutide preserved lean mass and physical function while producing greater fat loss during the active treatment period. Perhaps even more compelling: when patients discontinued semaglutide but continued enobosarm as monotherapy, the compound prevented the regain of we-ight lost. That rebound-prevention signal could be significant in a space where GLP-1 discontinuation rates remain a persistent challenge for patients and prescribers alike. A Fully Enrolled Trial and Two Data Windows Ahead
The Phase 2b PLATEAU clinical trial represents the next major milestone for enobosarm… and the enrollment numbers tell their own story. The company didn't just reach its target — it exceeded it, enrolling 239 patients against a goal of 200. PLATEAU is evaluating enobosarm 3mg versus placebo in older patients (age 65+) with obesity (BMI ≥ 35) who are initiating semaglutide treatment. The primary endpoint is the percent change from baseline in total body we-ight at 68 weeks. Key secondary endpoints include total fat mass, total lean mass, physical function via stair climb test, mobility disability assessment, bone mineral density, HbA1c, and insulin resistance… a broad panel that should give the market a comprehensive view of enobosarm's effect profile. The study's principal investigator is Steven Heymsfield, MD, a Professor and Director of the Body Composition-Metabolism Laboratory at Pennington Biomedical Research Center — the same researcher who led the earlier Phase 2b QUALITY study. Two data readouts are on the horizon. An interim analysis assessing lean body mass and fat mass at the 32-week mark is expected in the first quarter of calendar year 2027. Final topline results are expected in the fourth quarter of calendar year 2027. Each readout represents a distinct window that could serve as a potential catalyst for renewed attention toward (VERU). The company also secured a clinical supply agreement with Novo Nordisk for the PLATEAU trial — a detail worth noting for its operational significance, even though it does not imply endorsement of the combination approach. And this week, the company is scheduled to present at the 2026 Cantor Global Healthcare Conference on September 9, 2026 — putting the enobosarm story in front of a focused healthcare audience at a timely moment. An IP Portfolio Built for the Long Run
Strong clinical data means little without the intellectual property to protect it… On that front, the company recently received a USPTO Notice of Allowance for a key methods-of-use U.S. patent covering enobosarm in combination with semaglutide for quality we-ight loss. When issued, this patent will provide protection until at least October 2044. The allowed claims span a wide range of treatment regimens — concurrent therapy with semaglutide, add-on therapy, and enobosarm monotherapy after semaglutide discontinuation. They also cover a broad set of clinical outcomes: preservation of lean mass, enhancement of fat loss, physical function improvement, bone preservation, insulin resistance improvement, HbA1c, and prevention of we-ight regain after GLP-1 RA discontinuation. That's not a narrow filing… that's a comprehensive IP position around the entire enobosarm-plus-GLP-1 treatment paradigm. The company's patent portfolio also includes already-issued composition-of-matter patents specific to enobosarm's polymorph, along with pending applications directed to a modified-release enobosarm formulation that, if issued, could extend protection until at least May 2046. Worldwide patent applications covering enobosarm in combination with we-ight loss dr-ugs beyond semaglutide are also being pursued — suggesting a multi-compound IP strategy that looks well beyond the current trial and well beyond a single GLP-1 RA partner molecule. That kind of forward-looking IP architecture matters in a dr-ug development space where the competitive field is expanding rapidly and the pipeline winners will be determined as much by their exclusivity as their efficacy. Meanwhile, according to Morningstar, (VERU) has a market cap of under approximately $50M — a figure that looks modest against the scope of the addressable GLP-1 combination therapy space and the clinical milestones ahead. 7 Reasons Why We’re Watching (VERU) This Morning —Tuesday, September 8, 2026…
1. Small-Float: According to Yahoo Finance, less than 16M shares exist in the public float, the potential exists for big moves if demand begins to shift. 2. Fully Enrolled Phase 2b PLATEAU Trial: The company exceeded its enrollment target by enrolling 239 patients against a goal of 200, suggesting strong investigator and patient enthusiasm for the enobosarm-plus-semaglutide combination. 3. Two Upcoming Data Readouts: An interim analysis is expected in Q1 2027 and final topline data in Q4 2027 — each a distinct potential catalyst for renewed attention. 4. Positive Phase 2b QUALITY Results: The completed QUALITY study demonstrated that enobosarm plus semaglutide preserved lean mass, improved fat loss, and — as monotherapy — prevented we-ight regain after GLP-1 RA discontinuation. 5. U.S. Patent Protection to October 2044: A USPTO Notice of Allowance covers a comprehensive range of enobosarm-plus-semaglutide treatment regimens, with additional pending applications extending potential protection to May 2046. 6. Novo Nordisk Clinical Supply Agreement: A supply agreement with Novo Nordisk for the PLATEAU trial signals operational credibility and ensures consistent dr-ug supply throughout the study. 7. Analyst Coverage With Significant Upside Potential: Canaccord Genuity analyst Edward Nash carries a $25 target on VERU — representing significant upside from its recent $2.65 range. Take A Closer Look At (VERU) While It’s Still Early…
The GLP-1 we-ight loss space is one of the fastest-expanding segments in healthcare… projected to grow from $27.5B in 2026 toward nearly $48.8B by 2030, according to Grand View Research. But the conversation is evolving — from how much we-ight a patient can lose to how well they lose it. That shift from quantity to quality is exactly the lane Veru Inc. (NASDAQ: VERU) has chosen to build in. A pipeline focused on the next unmet need in obesity treatment. A fully enrolled Phase 2b trial with 239 patients and two data readouts approaching. A growing IP portfolio protected well into the 2040s. And a float small enough to amplify any meaningful shift in demand… For anyone watching the GLP-1 combination therapy space closely, this is a name that deserves a closer look as the calendar turns toward 2027. (VERU) is the first name on our screen this morning. Take a look at it while it’s still early. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter |
0 التعليقات:
إرسال تعليق